VSTM2L and neuroblastoma: Meanwhile, three independent neuroblastoma cohorts (Kocak, SEQC, TARGET) consistently revealed significantly elevated expression of NRCAM, VSTM2L, SLIT3, and ALCAM in Stage 4S tumors (Fig. 3B).